The U.S. Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), has awarded up to $37 million in funding to the Thymus Rejuvenation project, led by Thymmune Therapeutics Inc.
Arialys Therapeutics Inc. has closed $58 million in seed financing. The proceeds of the financing will be used to advance new precision medicines that specifically block pathogenic autoantibodies in the central nervous system (CNS) with the aim of treating neuropsychiatric diseases driven by autoimmunity.
“From one to many” is how Actio Biosciences Inc. describes its approach to drug development. The firm emerged with a $55 million series A financing and an eye for biological targets found in both rare and common diseases, starting with TRPV4, a target associated with Charcot-Marie-Tooth disease type 2C and other bone diseases.
Mironid Ltd. has announced an extension of its series A financing round to support its development of small-molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The company will use the proceeds of the financing to advance its lead discovery program through IND-enabling studies.
Emerging from stealth mode, new immuno-oncology company Dotbio Pte. Ltd. closed an oversubscribed $5.6 million pre-series A round to accelerate development of its multifunctional and intracellular antibody therapies.
The identification of new targets in diseases of the central nervous system (CNS) such as Alzheimer’s and Parkinson’s – conditions which continue to have significant unmet needs – has taken a small step forward as one company, Violet Therapeutics Inc., plans to put $10.6 million in seed funding toward building out a pipeline based on technologies that elucidate the way cells interact amongst one another.
A team of scientists led by The Wistar Institute has been awarded a 5-year National Cancer Institute (NCI) Program Project Grant valued at more than $12 million to explore the role of Epstein-Barr virus (EBV) in epithelial cancers. The project, which brings together scientists from The Wistar Institute and Harvard University, will focus entirely on the EBV-epithelial cancer link and look at metabolic and epigenetic vulnerabilities simultaneously.
RSS
